Article

Olopatadine 0.2% provides extended efficacy during peak pollen periods

Fort Lauderdale, FL-A new formulation of an anti-allergy medication, olopatadine HCl ophthalmic solution 0.2% (Patanol II, Alcon Laboratories), provides two important advantages. It allows once-daily dosing, which increases patient compliance, and maintains the level of effectiveness of the original formulation, olopatadine 0.1%, during peak pollen seasons for an extended period up to 24 hours, according to Jack Greiner, DO, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Study shows genetic link between instant coffee consumption and increased risk of dry AMD
June 20th 2025

Study shows genetic link between instant coffee consumption and increased risk of dry AMD

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Meeting the need for low vision services with wearable tech
June 19th 2025

Q&A: Meeting the need for low vision services with wearable tech

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/Justlight)
June 18th 2025

Ruth Hogg, PhD, on what retinal imaging can tell clinicians about the brain and body

(Image credit: AdobeStock/peopleimages.com) Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
June 18th 2025

Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

© 2025 MJH Life Sciences

All rights reserved.